Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameluz application duration study for acral actinic keratoses
2019-003150-86Phase 3Unknown
- Sponsor
- Royal Cornwall Hospitals NHS Trust
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of 5-aminolevulinic acid in actinic keratosis (AK) (2 arms), sponsored by Royal Cornwall Hospitals NHS Trust. Primary endpoint: Full clearance of individual acral actinic keratosis lesions at 3 months. Status: unknown.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2019-003150-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003150-86.